Remove Biopharma Remove Competition Remove Specialization
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.

article thumbnail

Biopharma struggling to find talent with adequate digital skills

European Pharmaceutical Review

A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Major M&A deals on 2023 agenda, says report

European Pharmaceutical Review

In the first 11 months of 2022, biopharma M&A value dropped by 42 percent compared to 2021, with Pfizer’s acquisition of Biohaven , the single largest deal up to December 2022. Alliances were a significant focus for biopharma and companies’ M&A strategies in 2022. Biopharma alone held over $1.4

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.

Pharma 123
article thumbnail

Improve Your Health, Meet in Person

PM360

The health-conscious among us pay special attention to actively managing our sleep, exercise, vitamins, etc. Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. The list goes on.

article thumbnail

Three Sales Compensation Pitfalls to Avoid for a Rare Disease Product Launch

The Marketing Advantage

Lack of Data and/or Proxies There is typically little to no competitive data available With over 95% of the over 7,000 estimated rare diseases having no treatment, these products typically have no competition and thus no competitive data. This, in turn, calls for a more expert and specialized sales force.

Sales 52
article thumbnail

Five IDNs to watch in 2023

Clarivate

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.